SCHEMBL7993039

SCHEMBL7993039

Cn1c(-c2cccnc2)nc(-c2ccc(-c3ncon3)cc2)c1Sc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.60
KCNH2 Q12809 2/20 0.60
PPARA Q07869 1/20 0.41
NPY5R Q15761 2/20 0.40
MAPKAPK2 P49137 1/20 0.37
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP3A4 P08684 2/20 0.34
GAA P10253 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8005123 0.89 FAAH (0.51) FAAHKCNH2ALDH1A1GAACYP1A2
SCHEMBL1303011 0.89 FAAH (0.50) FAAHKCNH2KDM4EMEN1ALDH1A1
SCHEMBL8002873 0.87 FAAH (0.51) FAAHKCNH2ALDH1A1SMN1; SMN2NPC1
SCHEMBL12106726 0.85 FAAH (0.47) FAAHKCNH2ALDH1A1CYP3A4CYP2C19
SCHEMBL7993038 0.84 FAAH (0.62) FAAHKCNH2KDM4EMEN1KMT2A
SCHEMBL8008446 0.81 MKNK1 (0.47) FAAHNPY5RKMT2ACDC25ACDC25B
SCHEMBL1303886 0.81 FAAH (0.48) FAAHKCNH2KDM4EMEN1ALDH1A1
SCHEMBL12106262 0.81 FAAH (0.58) FAAHKCNH2NPY5R
SCHEMBL7993050 0.80 FAAH (0.44) FAAHKCNH2ALDH1A1MAPK1SMN1; SMN2
SCHEMBL1304324 0.80 FAAH (0.43) FAAHKCNH2SLC2A1SLC2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885KCNH2 1076/4885PPARA 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.